- Ramp raised $1.85 billion at a $60 billion valuation, led by Dragoneer with Thrive Capital, Founders Fund, Sands Capital and Avenir as co-leads, four months after a $750 million round valued it at $44 billion. Annualised revenue has reached $2 billion, up from $1.5 billion in June.
- The markup is earned rather than assumed. At $44 billion on $1.5 billion the company traded at roughly 29 times revenue; at $60 billion on $2 billion it is about 30 times. The valuation rose 36% because revenue rose 33%, so the multiple barely moved.
- The customer base grew to more than 85,000 companies from 70,000 at the start of June, and headcount to 1,900 from 1,700, following launches in the United Kingdom and Canada and two acquisitions earlier this year.
- New investors signal listing intent. Co-chief executive Eric Glyman pointed to Dragoneer, Fidelity Management and Research and Capital International as crossover investors that typically buy in the years before a public offering and hold through the debut, and said the capital moves the company closer to its IPO goals without naming a date.
What Happened?
Founded in 2019, Ramp provides products helping businesses manage bills, collect revenue and identify fraud. Glyman said that just as companies have systems to manage payroll and vendor spend, organisations will need the same for AI. Recent releases include a product routing tasks to lower-cost models where appropriate, and a platform letting finance and engineering teams view and manage company AI spending. The fresh capital will fund more advanced AI products, which Glyman said require more money to develop, alongside continued hiring and possible further acquisitions.
Why It Matters?
The multiple holding steady is the detail that distinguishes this from the deals that have failed. Firmus Grid was worth roughly $10 billion in August and sought $30 billion in October without a commensurate operational change, and public investors refused twice within 48 hours. Ramp’s valuation rose because the business grew at almost exactly the same rate, which means the private market is still marking up but, in this case, on fundamentals rather than sentiment. Thirty times revenue is demanding and it is also the level at which Iambic Therapeutics cleared its IPO this week, against the 588 times Firmus was asking. That figure is emerging as something like a market-clearing multiple for growth businesses with real revenue. The product positioning is more interesting than it appears and is genuinely hedged within the AI theme. Ramp is building cost controls for AI spending, including routing work to cheaper models. Demand for that increases when AI budgets come under scrutiny, which is precisely what is happening: a Federal Reserve president has warned the buildout may be overheating the economy, CoreWeave’s bonds have gone distressed, and the chairman of a $72 billion industrial group said he will slow AI investment because his businesses have no common use case. A company selling discipline to AI spenders benefits whether budgets grow or get examined, which is an unusual position in a sector where most participants need spending to accelerate. The crossover investors are the clearest IPO signal available. Firms that specialise in pre-listing rounds and hold through the debut are underwriting the eventual public valuation, which means $60 billion is a number they expect to defend in public markets. Given what has happened to AI-adjacent listings this month, that is a meaningful commitment.
What Next?
No listing date has been given, but the composition of the cap table suggests preparation is underway and the IPO window has proven open this month for companies priced sensibly. Watch whether revenue growth holds near the current pace, since the valuation rests on it rather than on multiple expansion. Adoption of the AI spend management products is the thesis to track, and it is the part of the business least dependent on AI budgets continuing to grow. Further acquisitions are possible, and the UK and Canada launches are the near-term test of whether the model travels.
Affected Tickers and Coins: BILL, AXP
Source: Bloomberg
